128 results on '"Marra, Antonio"'
Search Results
2. Genomic and epigenomic basis of breast invasive lobular carcinomas lacking CDH1 genetic alterations
3. The role of APOBEC3B in lung tumor evolution and targeted cancer therapy resistance
4. RB1 Genetic Alterations in Estrogen Receptor–Positive Breast Carcinomas: Correlation With Neuroendocrine Differentiation
5. Effect of age on safety and efficacy of novel cancer drugs investigated in early-phase clinical trials
6. The evolving landscape of metastatic HER2-positive, hormone receptor-positive Breast Cancer
7. Clinicopathologic and genomic features of lobular like invasive mammary carcinoma: is it a distinct entity?
8. Prognostic significance of HER2-low status in HR-positive/HER2-negative advanced breast cancer treated with CDK4/6 inhibitors
9. Expanded genetic testing of GIST patients identifies high proportion of non-syndromic patients with germline alterations
10. Somatic estrogen receptor [alpha] mutations that induce dimerization promote receptor activity and breast cancer proliferation
11. Nonlobular Invasive Breast Carcinomas with Biallelic Pathogenic CDH1 Somatic Alterations: A Histologic, Immunophenotypic, and Genomic Characterization
12. TERT promoter mutations and gene amplification in endometrial cancer
13. Variant allele frequency: a decision-making tool in precision oncology?
14. The CDK4/6 inhibitors biomarker landscape: The most relevant biomarkers of response or resistance for further research and potential clinical utility
15. Clinicopathological features and survival outcomes of luminal-like breast tumors with estrogen receptor loss at metastatic recurrence: A case-control study
16. Platinum-based chemotherapy and PARP inhibitors for patients with a germline BRCA pathogenic variant and advanced breast cancer (LATER-BC): retrospective multicentric analysis of post-progression treatments
17. Clinical utility of genomic signatures for the management of early and metastatic triple-negative breast cancer
18. Integration of clinical sequencing and immunohistochemistry for the molecular classification of endometrial carcinoma
19. Histopathologic features and molecular genetic landscape of HER2-amplified endometrial carcinomas
20. Development and validation of an analytical method to ensure quality requirements of hydrolysed proteins intended for agricultural use as biostimulants
21. The clinical behavior and genomic features of the so-called adenoid cystic carcinomas of the solid variant with basaloid features
22. Privacy preserving data sharing and analysis for edge-based architectures
23. Home Sweet Home: CEOs Acquiring Firms in Their Birth Countries.
24. Development and Validation of a Natural Language Processing Algorithm for Extracting Clinical and Pathological Features of Breast Cancer From Pathology Reports.
25. Clinical actionability of BRCA2 alterations in uterine leiomyosarcoma: a molecular tumor board case report and a cBioPortal comprehensive analysis.
26. Treatment of ovarian clear cell carcinoma with immune checkpoint blockade: a case series
27. Efficacy and Safety of Anti-PD-1 Immunotherapy in Patients Aged ≥ 75 Years With Non–small-cell Lung Cancer (NSCLC): An Italian, Multicenter, Retrospective Study
28. Ask a(n)droid to tell you the odds: probabilistic security-by-contract for mobile devices
29. Use of Antibody–Drug Conjugates in the Early Setting of Breast Cancer.
30. High‐throughput molecular assays for inclusion in personalised oncology trials – State‐of‐the‐art and beyond.
31. PARP Inhibitors for Breast Cancer Treatment: A Review.
32. Expression of tumor-associated antigens in breast cancer subtypes
33. Digital Waste Disposal: an automated framework for analysis of spam emails
34. Evaluation of the Geographical Accessibility of Genome-Matched Clinical Trials on a National Experience.
35. KIT genetic alterations in breast cancer.
36. Baseline Tumor Size as Prognostic Index in Patients With Advanced Solid Tumors Receiving Experimental Targeted Agents.
37. Organizational structure and earnings quality of private and public firms
38. Peripheral blood lymphocytes predict clinical outcomes in hormone receptor-positive HER2-negative advanced breast cancer patients treated with CDK4/6 inhibitors.
39. Genomic Profiling Reveals Germline Predisposition and Homologous Recombination Deficiency in Pancreatic Acinar Cell Carcinoma.
40. Predicting Response to Antibody Drug Conjugates: A Focus on Antigens' Targetability.
41. The Role of Mesothelin as a Diagnostic and Therapeutic Target in Pancreatic Ductal Adenocarcinoma: A Comprehensive Review
42. Solar Dish Concentrator: A Case Study at the Energy Center Rooftop.
43. Resistance to anti-PD-1-based immunotherapy in basal cell carcinoma: a case report and review of the literature
44. Molecular Biomarkers of Disease Outcomes and Mechanisms of Acquired Resistance to First-Line Osimertinib in Advanced EGFR-Mutant Lung Cancers.
45. Board Monitoring and Earnings Management Pre- and Post-IFRS
46. Exploiting If This Then That and Usage Control obligations for Smart Home security and management.
47. Corporate Boards, Audit Committees, and Earnings Management: Pre- and Post-SOX Evidence
48. ATM Germline-Mutated Gastroesophageal Junction Adenocarcinomas: Clinical Descriptors, Molecular Characteristics, and Potential Therapeutic Implications.
49. Organized Crime and Firms' Financial Statements: Evidence from Criminal Investigations in Italy.
50. Refining risk stratification in HR-positive/HER2-negative early breast cancer: how to select patients for treatment escalation?
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.